Archive for the ‘italy retractions’ Category
Alberto Carpinteri is something of a Renaissance man.
Along with championing a highly controversial form of energy generation called “piezonuclear fission,” which involves crushing rocks, the engineer has argued that the Shroud of Turin really is as old as Jesus, but carbon dating was thrown off by an earthquake.
Not everyone agrees with his ideas: In 2012, more than 1,000 scientists signed a petition asking the Italian National Institute of Metrological Research (or INRIM, of which Carpinteri was director at the time) not to fund piezonuclear fission.
Carpinteri was also editor in chief of the journal Meccanica until 2014, when Luigi Gambarotta took over. Now, Meccanica is retracting 11 of its former EIC’s papers, including the one on the Shroud, and a number on piezonuclear fission, which Wired Italy put on their list of “most famous science hoaxes.” The reason? According to the notice, “the editorial process had been compromised.” Read the rest of this entry »
Surgeon Paolo Macchiarini, who is under investigation for allegedly downplaying dangers of an experimental surgery, has been cleared of some misconduct allegations by the Karolinska Institutet in Stockholm.
Macchiarini, a thoracic surgeon, has made headlines for repairing damaged airways using tracheas from cadavers and even synthetic tracheas, both treated with the patients’ own stem cells to assist in the transplant.
In a letter to Vice-Chancellor Anders Hamsten dated last month, KI’s Ethics Council refuted a number of accusations leveled against Macchiarini by Pierre Delaere at KU Leuven in Belgium, who had suggested the surgeon had engaged in scientific misconduct, including fabricating data.
The Ethics Council, however, disagreed:
The investigation, which came to light in late 2013, had focused on eight papers thought to demonstrate evidence of image manipulation.
The latest paper, in the European Journal of Cancer, studied mice with a genetic alteration associated with lipomas (benign fatty growths) in humans.
A 2014 Cancer Cell paper became the subject of an erratum in January 2015, shortly after PubPeer members began criticizing the data. However, many issues brought up by commenters weren’t addressed in the correction notice, including a figure that might be two experiments spliced together to look like one.
The paper, led by Guido Franzoso at Imperial College London, claims that a new cancer drug called DTP3 kills myeloma cells “without causing any toxic side effects,” according to a press release from the school. Guido Franzoso is the founder of Kesios Therapeutics, a drug company which is set to begin clinical trials on DTP3.
The correction indicates that Western blots were cropped badly, which omitted several panels discussed in the text, while an “extra time point” was included accidentally. An antibody was also omitted from the description of the procedure.
PubPeer commenters have noticed additional issues, such as a criticism of figure 3D, which were not included or changed in this correction.
According to the notice, the senior author told the journal that the data came from the lab Li used to work in at the University of Rome Tor Vergata, but the P.I. in Italy didn’t know about the paper.
Two papers by an overlapping group of researchers in Italy have been retracted for manipulated figures.
In late 2013, perennial tipster Clare Francis sent their concerns about several papers, including the two that have been retracted, by authors who frequently publish together. One of the papers, in the Journal of Neurochemistry, is from a team led by Ferdinando Nicoletti; four other papers from the group have been criticized on PubPeer for image manipulation, which he addressed via email with us.
The second retracted paper, from the Journal of Immunology, has shares one author with the first: Patrizia Di Iorio of the University of Chieti, though according to Nicoletti she had no role in preparing the figures.
Here’s the April 2014 notice for “Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways” in the Journal of Neurochemistry. It’s behind a paywall, but the journal has assured us this is against policy and they will be fixing it shortly:
Read the rest of this entry »
A retracted 2008 paper originally flagged by Clare Francis has been republished in Environmental Health Perspectives with updated figures and new data.
According to the editor’s note appended to the newly published paper, there was no evidence of intentional misconduct on the part of the authors. The new paper went through peer review as an entirely new submission, and comes to the same conclusion as the original: Read the rest of this entry »
The long-running feud between Italian physicists Ignazio Ciufolini and Lorenzo Iorio (which we’ve covered here and here) turned up a notch in November, when Ciufolini filed a defamation lawsuit against Iorio.
You can read the full lawsuit here (in Italian). The gist is this: Iorio accused Ciufolini of criticizing the work of other physicists on ArXiv.org under two separate pseudonyms (in a letter which the Journal of the Association for Information Science and Technology, which published his claims, later retracted, saying it was a matter better handled locally). Iorio later left critical comments on articles about Ciufolini on the Science blog, Neuroskeptic, and an Italian newspaper La Repubblica‘s website.
This fight has a long history, despite the two having published articles together in the past. In 2004, Ciufolini’s lawyer sent Iorio a vaguely threatening letter (also in Italian) that had no specifics about what Iorio was doing wrong. Iorio described to us what the letter referred to:
Read the rest of this entry »
Several months after a drug company cancelled development of a potential diabetes cure because it found evidence that a biotech they had recently acquired had committed misconduct in studies of the drug, two retractions of relevant studies have appeared.
The research involves DiaPep277, which, as Josh Levy explained here in September, “would cause the immune system to stop attacking beta cells,” the cells in the pancreas that produce insulin. But Hyperion Therapeutics, which had acquired DiaPep277 developer Andromeda Biotech in June, announced in September that it had
uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result.
The retractions are both of papers published in Diabetes Care in May 2014. Here’s the notice for “Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial:” Read the rest of this entry »
A group of gastroenterology researchers in Italy has lost their 2010 paper in Internal and Emergency Medicine, the journal of the Italian Society of Internal Medicine, for plagiarizing and duplicate publication.